Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fordine
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Huperzine A CR Tablets Safety and Efficacy In Mild-Moderate Alzheimer’s Dementia
Details : Huperzine A is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 15, 2025
Lead Product(s) : Fordine
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Huperzine A is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cognitive Dysfunction-associated with Brain Injuries.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 26, 2024
Lead Product(s) : Fordine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Zhejiang Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Huperzine A is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 26, 2024
Lead Product(s) : Fordine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Zhejiang Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Huperzine A is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Postoperative Cognitive Complications-associated with Subarachnoid Hemorrhage.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 29, 2022
Lead Product(s) : Bromihexine HCl
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Second Affiliated Hospital of Wenzhou Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Study on the Pharmacokinetics of Bromine Hexane Hydrochloride Tablets in Healthy Adults
Details : Bromihexine HCl is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 17, 2020
Lead Product(s) : Bromihexine HCl
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Second Affiliated Hospital of Wenzhou Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ginkgo Biloba
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ginkgo Biloba is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Angina Pectoris-associated with Depression.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 27, 2020
Lead Product(s) : Ginkgo Biloba
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bromhexine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Recipient : Second Affiliated Hospital of Wenzhou Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Bromhexine HCl is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Pneumonia-associated with COVID-19.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 18, 2020
Lead Product(s) : Bromhexine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Recipient : Second Affiliated Hospital of Wenzhou Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable